Prevention Better Than Cure? AC Immune's Parkinson’s Vaccine Approach

With a broad pipeline focused on neurodegenerative disease, AC Immune is about to begin a Phase II program investigating an alpha-synuclein-targeted peptide vaccine with a diagnostic to stratify patients.    

prevention
• Source: Shutterstock

Lausanne, Switzerland-based AC Immune SA thinks the best potential for treating Parkinson’s disease and other neurodegenerative diseases lies in prevention, using a combination of therapeutic vaccines and diagnostics that can distinguish one proteinopathy from another.

In a recent interview with In Vivo, CEO Andrea Pfeifer explained why recent advancement with alpha-synuclein PET tracer ACI-12589 offers...

More from New Science

More from In Vivo